Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 10/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | NOS3 | P29474 | 3/20 | 0.63 |
| ▸ | NOS1 | P29475 | 3/20 | 0.63 |
| ▸ | NOS2 | P35228 | 3/20 | 0.63 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42907 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29567585 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL1795728 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL42906 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL6215515 | 0.98 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL16714153 | 0.98 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL6216515 | 0.98 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31369541 | 0.91 | GRIA2 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30291566 | 0.90 | NOS3 (0.52) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19943581 | 0.88 | NOS3 (0.49) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024163643-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | claimed |
| CN-115768456-A | TSLP-specific bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-03-07 | — | — | CN | claimed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | claimed |
| WO-2023288017-A2 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | claimed |
| WO-2023288019-A2 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | claimed |
| EP-4090670-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | claimed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC7A5 3470/4885PTGS1 908/4885ALPI 452/4885 |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | SLC7A5 3749/4885PTGS1 1171/4885ALPI 3529/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC7A5 3470/4885PTGS1 908/4885ALPI 452/4885 |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL36G, IL15RA | SLC7A5 634/4885PTGS1 1590/4885ALPI 3076/4885 |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | SLC7A5 1924/4885PTGS1 1206/4885ALPI 2346/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC7A5 3470/4885PTGS1 908/4885ALPI 452/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | SLC7A5 1439/4885PTGS1 1487/4885ALPI 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.